Evolus reported Q2 2026 earnings that exceeded analyst expectations, with EPS printing above forecast and the company raising its 2026 outlook. The stock advanced on the results, reflecting investor confidence in the company's execution trajectory.
Business & M&A
Evolus Q2 Revenue Beats Forecast, Raises 2026 Outlook
Evolus delivered EPS above consensus and raised full-year guidance, signaling sustained momentum in the neuromodulator market.
1-YEAR MOVE
EOLS
▼15.6%
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| EOLS | Evolus | −15.6% |
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Evolus raised full-year 2026 guidance after beating Q2 revenue forecasts.
For medspa owners, Evolus's beat underscores the durability of Jeuveau demand in a competitive toxin landscape. The company's ability to grow revenue and improve profitability—moving toward sustained positive earnings—validates the value of a third-major player in the market. Evolus Rewards loyalty rebates and favorable per-unit economics relative to AbbVie and Galderma continue to drive adoption among independent practices seeking margin protection.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.